Thrombolytic therapy for acute ischemic stroke

American Journal of Cardiovascular Drugs

Volumn 1, Issue 4, 2001, Pages 281-292

  Cornu, Catherine ^a,c   Amsallem, Emmanuel ^a   Serradj Jaillard A, Assia ^b  

^a UNIVERSITÉ LYON 1   (France)

^b UNIV GRENOBLE ALPES   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; SARUPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE DISEASE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; FIBRINOLYTIC THERAPY; HUMAN; META ANALYSIS; MORTALITY; POSTMARKETING SURVEILLANCE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ACUTE DISEASE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; META-ANALYSIS; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 1842616160     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/00129784-200101040-00006     Document Type: Review

References (45)

1. Murray JL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-76
2. Stroke Unit Trialists? Collaboration. Organised inpatient (stroke unit) care for stroke [online]. Cochrane Database Systems Review 2000; 2: CD000197. Avaiable from : URL: http://www.update-software.com/abstract/ab00197.htm.
3. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcatuaneous heparin, both or neither mong 19 435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-81
4. Chinese Acute Stroke Trial Collaborative Group (CAST). Randomised placebocontrolled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997; 349 1641-9
5. Olsen TS. Regional cerebral blood flow after occlusion of the midddle cerebral artery. Acta Neurol Scand 1986; 73: 321-37
6. Fieschi C, Argentino C, Lenzi GL, et al. Clinical and instrumental evaluation of patients with ischaemic stroke within the first six hours. J Neurol Sci 1989; 91: 311-21
7. Baird AE, Austin MC, McKay WJ, et al. Changes in cerebral tissue perfusion during the first 48 hours of ischaemic stroke: relationship to clinical outcome. J Neurol Neurosurg Psychiatry 1996; 61: 26-9
8. Koroshetz WJ, Moskowitz MA. Emerging treatments for stroke and the ischaemic penumbra. Trends Pharmacol Sci 1996; 17: 227-33
9. Britton M, Rödén A. Progression of stroke after arrival at hospital. Stroke 1985; 16: 629-32
10. Toni D, Fiorelli M, Gentile M, et al. Progressing neurological deficit secondary to acute ischaemic stroke. Arch Neurol 1995; 52: 670-5
11. Yasaka M, O?Keefe GJ, Chambers BR, et al. Streptokinase in acute stroke: effect on reperfusion and recanalisation. Neurology 1998; 50 626-32
12. Infeld B, Davis SM, Donnan GA, et al. Streptokinase increases luxury perfusion after stroke. Stroke 1996; 27 1524-9
13. Baron JC. Perfusion thresholds in human cerebral ischemia: historical perspective and therapeutic implications. Cerebrovasc Dis 2001; 11 Suppl. 1: 2-8
14. Fibrinolytic Therapy Trialists (FTT) Collaborative Group, Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients [published erratum appears in Lancet 1994; 343: 742]. Lancet 1994; 343: 311-22
15. European Cooperative Acute Stroke Study (ECASS), Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995; 274: 1017-25
16. del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: A phase II randomised trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998; 29: 4-11
17. Furlan A, Higashida R, Wechsler L, PROACT Investigators, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II Study: a randomized controlled trial. JAMA1999; 282: 2003-2011.
18. Haley Jr EC, Brott TG, Sheppard GL, et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group. Stroke 1993; 24 (7): 1000-4
19. Yamaguchi T, Hayakawa T, Kiuchi H, et al. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis 1993; 3 (4): 269-72
20. Mori E, Yoneda Y, Tabuchi M. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42: 976-82
21. The Multicenter Acute Stroke Trial - Europe Study Group. Thrombolytic therapy with streptokinase in acute ischaemic stroke. New Engl J Med 1996; 335: 145-50
22. Morris AD, Ritchie C, Grosset DG, et al. A pilot study of Streptokinase for acute cerebral infarction. Q J Med 1995; 88 (10): 727-31
23. Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischaemic stroke with relationship to time of administration. JAMA 1996; 276: 961-6
24. The NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 1995; 333: 1581-7
25. Multicentre Acute Stroke Trial: Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346: 1509-14
26. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). European Cooperative Acute Stroke Study II. Lancet 1998; 352: 1245-51
27. Clark WM, Albers GW. The ATLANTIS rt-PA (Alteplase) acute stroke trial: final results [abstract]. Cerebrovasc Dis 1999; 9 Suppl. 2: 234
28. Clark WM, Wissman S, Albers GW et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. JAMA 1999; 282 (21): 2019-26
29. Clark WM, Albers GW, Madden KP et al. The rtPA (Alteplase) 0- to 6-Hour acute stroke trial, Part A (A0276g) Results of a double-blind, placebo-controlled, multicenter study. Stroke 2000; 31: 811-6
30. Wardlaw JM, del Zoppo G, Yamaguchi T. Thrombolysis for acute ischaemic stroke Cochrane database. Systematic Revues 2000; 2: CD000213 http://www.updatesoftware. com/abstracts/ab000213.htm, [Acccessed 1999 Mar]
31. Cucherat M, Boissel JP, Leizorovicz A, et al. Easy MA: a program for the metaanalysis of clinical trials. Comput Methods Programs Biomed 1997; 53: 187-90
32. Sinclair JC, Bracken MB. Clinically useful measures of effect in binary analysis of randomized trials. J Clin Epidemiol 1994; 47: 881-9
33. Lu M, Tilley BC, for the NINDS t-PA Stroke Trial Study Group. Use of odds ratio or relative risk to measure a treatment effect in clinical trials with multiple correlated binary outcomes: data from the NINDS t-PA stroke trial. Stat Med 2001; 20: 1891-901
34. Altman DG, Deeks JJ, Sackett DL. Odds ratios should be avoided when events are common [letter]. BMJ 1998; 317: 1318
35. Cornu C, Boutitie F, Candelise L, et al. Streptokinase in acute ischemic stroke: an individual patient data meta-analysis: The thrombolysis in acute stroke pooling project. Stroke 2000; 31: 1555-60
36. Jaillard A, Cornu C, Durieux A, et al. Hemorrhagic transformation in Acute Ischemic Stroke. The MAST-E Study. Stroke 1999; 30: 1326-32
37. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997; 28: 2109-18
38. Société Française Neurovasculaire, Recommandations pour l?utilisation du traitement thrombolytique intraveineux dans l?accident ischémique cérébral. Presse Med 2000; 29: 372-8
39. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke. The standard treatment with alteplase to reverse stroke (STARS) Study. JAMA 2000; 283: 1145-50
40. Grond M, Stenzel C, Schmülling S, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998; 29: 1544-9
41. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283: 1151-8
42. Buchan AM, Barber PA, Newcommon N, et al. Effectiveness of t-PA in acute ischemic stroke: Outcome relates to appropriateness. Neurology 2000; 54: 679-84
43. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome. The NINDS rt-PA Stroke Study. Neurology 2000; 55: 1649-55
44. Schellinger PD, Jansen O, French JB, et al. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI. Stroke 2000; 31: 1318-28
45. Galbraith RF. A note on the graphical presentation of estimated odds ratio from several clinical trials. Stat Med 1988; 7 (8): 889-94